REG - Arecor Therapeutics - Non-Executive Director Board Change

Arecor TherapeuticsAnnouncement

02/06/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250602:nRSB9061Ka&default-theme=true

RNS Number : 9061K  Arecor Therapeutics PLC  02 June 2025

Arecor Therapeutics plc

("Arecor" or the "Company")

 

NON-EXECUTIVE DIRECTOR BOARD CHANGE

 

-    Dr Alan E Smith, CBE, FRS, Ph.D., to retire as he steps down from
Non-Executive Director role on Arecor's Board

 

Cambridge, UK, 2 June 2025: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical company advancing today's therapies to enable healthier
lives, today announces that Dr Alan Smith, who has served as a Non-Executive
Director of Arecor for more than 17 years, has informed the Company that he
will not seek re-election and will retire from the Board at the forthcoming
annual general meeting to be held today, 2 June 2025.

 

Throughout his time at Arecor, Dr Smith has provided invaluable scientific and
strategic guidance as the Company has evolved from its early stages to a
clinical-stage company, underpinned by its proprietary Arestat™ technology
platform.

 

Andrew Richards, Non-Executive Chair of Arecor, said: "I would like to express
our sincere gratitude to Alan for his many years of dedicated service on the
Board and the exceptional scientific expertise and critical insights he has
brought to Arecor. His guidance to the team and the Board has been
instrumental in helping Arecor advance as a company. We wish him all the best
in his retirement."

 

Alan Smith, Non-Executive Director, Arecor, said: "I joined Arecor's Board
because I was so impressed with the company's understanding of the science
behind formulation, an area I know to be neglected at many biotech companies.
I am proud of what the company has achieved and confident in its eventual
success as it advances its promising pipeline of therapeutics that has the
potential to significantly improve patient care."

 

-ENDS-

 

For more information, please contact:

 

 Arecor Therapeutics plc                                 www.arecor.com
 Dr Sarah Howell, Chief Executive Officer                Tel: +44 (0) 1223 426060

                                                         Email: info@arecor.com (mailto:info@arecor.com)
 David Ellam, Chief Financial Officer                    Tel: +44 (0) 1223 426060

                                                         Email: info@arecor.com (mailto:info@arecor.com)

 Singer Capital Markets Advisory LLP (NOMAD and Broker)
 Phil Davies, Sam Butcher                                Tel: +44 (0) 20 7496 3000

 ICR Healthcare
 Chris Gardner, David Daley, Lindsey Neville             Tel: +44 (0) 20 3709 5700

                                                         Email: arecor@icrhealthcare.com (mailto:arecor@icrhealthcare.com)

 

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary technology platform, Arestat™, we are developing an internal
portfolio of proprietary products in diabetes and other indications, as well
as working with leading pharmaceutical and biotechnology companies to deliver
therapeutic products. The Arestat™ platform is supported by an extensive
patent portfolio.  For further details please see our website, www.arecor.com
(http://www.arecor.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAFLFVARVILIIE